Skip to main content
. Author manuscript; available in PMC: 2022 Apr 24.
Published in final edited form as: Neurotox Res. 2022 Jan 19;40(2):373–383. doi: 10.1007/s12640-021-00469-0

Fig. 5.

Fig. 5.

Prdx3 overexpression prevented motor impairment in the mild paralytic Gpx4NIKO model. Gpx4NIKO/PRDX3 and control Gpx4NIKO mice were treated with a low dose (single 45 mg/kg i.p. injection) of TAM to ablate Gpx4. a. Rotarod performance of Gpx4NIKO/PRDX3 and control Gpx4NIKO mice treated with the low dose of TAM. b. Hang-wire test performance of Gpx4NIKO/PRDX3 and control Gpx4NIKO mice treated with the low dose of TAM. n=6–8. *: p<0.05.